Hamilton Lane Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Hamilton Lane Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-96,474	Closed	-$721K	–	45
2023 Q2	$721K	Hold	96,474	–	–	0.32%	36
2023 Q1	$643K	Hold	96,474	–	–	0.21%	41
2022 Q4	$744K	Buy	96,474 +40,624	+73%	+$398K	0.27%	40
2022 Q3	$594K	Buy	55,850 +40,625	+267%	+$411K	0.22%	40
2022 Q2	$124K	Hold	15,225	–	–	0.05%	66
2022 Q1	$109K	Sell	15,225 -11,898	-44%	-$126K	0.02%	76
2021 Q4	$465K	Buy	+27,123	New	+$510K	0.06%	70

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hamilton Lane Advisors's RXRX Position: Q3 2023 in Review

Hamilton Lane Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 96,474 shares — an estimated $721K sold.

Hamilton Lane Advisors first reported a position in RXRX in Q4 2021 and held it in 7 quarters. The position peaked at $744K in Q4 2022. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

Hamilton Lane Advisors reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Hamilton Lane Advisors sold 96,474 Recursion Pharmaceuticals shares in Q3 2023, an estimated $721K.
Hamilton Lane Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Hamilton Lane Advisors's Recursion Pharmaceuticals position peaked at $744K in Q4 2022.
192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Hamilton Lane Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.